KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Pfizer (PFE) Restructuring Costs (2016 - 2026)

Pfizer has reported Restructuring Costs over the past 18 years, most recently at $49.0 million for Q1 2026.

  • Quarterly Restructuring Costs fell 92.77% to $49.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $978.0 million through Mar 2026, down 53.54% year-over-year, with the annual reading at $1.6 billion for FY2025, 21.99% down from the prior year.
  • Restructuring Costs was $49.0 million for Q1 2026 at Pfizer, down from $766.0 million in the prior quarter.
  • Over five years, Restructuring Costs peaked at $1.6 billion in Q4 2023 and troughed at -$74.0 million in Q2 2025.
  • The 5-year median for Restructuring Costs is $189.0 million (2022), against an average of $365.4 million.
  • Year-over-year, Restructuring Costs surged 19000.0% in 2022 and then crashed 122.92% in 2023.
  • A 5-year view of Restructuring Costs shows it stood at $177.0 million in 2022, then surged by 798.87% to $1.6 billion in 2023, then tumbled by 80.33% to $313.0 million in 2024, then soared by 144.73% to $766.0 million in 2025, then tumbled by 93.6% to $49.0 million in 2026.
  • Per Business Quant, the three most recent readings for PFE's Restructuring Costs are $49.0 million (Q1 2026), $766.0 million (Q4 2025), and $237.0 million (Q3 2025).